LEIDEN, Netherlands–(BUSINESS WIRE)–Ncardia, a leading provider of human iPSC-derived cell-based assays and
services for drug discovery and development, announced today the launch
of their DiscoverHIT drug screening platform. The new service enables
researchers to access human disease-relevant biology earlier in the drug
discovery process with the goal of bringing better medicines to patients
The DiscoverHIT Platform is a phenotypic drug screening platform
composed of four integrated modules:
- Disease models: Genetic and induced human iPSC-derived cardiac and
neural disease models
- Large-scale manufacturing: Controlled bioreactor-based manufacturing
to enable batch sizes compatible with high-throughput screening (HTS)
- Customized assay development: Generation and validation of
disease-relevant assays with clinically relevant readouts
- High-throughput screening: Robust HTS using qualified disease assays
in combination with high-content data acquisition and analysis
“Ncardia enables discovery with efficacy in mind from the start. To
realize this, drug developers need validated human iPSC products at
scale, disease models, the right assay systems and high-throughput
screening. We’ve brought these components together in the DiscoverHIT
platform.” stated Stefan Braam, CEO of Ncardia.
In addition to the four core modules of DiscoverHIT, Ncardia also offers
access to a comprehensive compound library, scientific consultation, and
the company’s newly founded training center, Ncardia Academy.
For more information on DiscoverHIT, visit ncardia.com/discoverhit.
believes that stem cell technology will help give patients faster access
to better and safer medicines by improving the drug discovery and
development process. The company has 15 years of experience in
developing and commercializing highly predictive human cellular assay
systems for safety and efficacy screening of drug candidates. Ncardia
operates globally and is based in Belgium, the Netherlands, Germany and
the USA. The company is privately held and established following the
merger of Pluriomics and Axiogenesis.
Thank you for donating to DutchNews.nl.
We could not provide the Dutch News service, and keep it free of charge, without the generous support of our readers. Your donations allow us to report on issues you tell us matter, and provide you with a summary of the most important Dutch news each day.Make a donation